Work

A Phase I study using Bortezomib with Weekly Idarubicin for the Treatment of Elderly (>60 YEARS) and Relapsed Patients with Acute Myeloid Leukemia (AML)

FWCI: 0.191
Cites:
Cited by: 2
Related to: 10